General Medicine and Specialty Medicine in notext: Interventional Neurology

• Publication date: June 2011

The report provides industry landscape, competitive landscape and industry trends data on the interventional neurology industry . The report provides comprehensive data on the major industry developments affecting the industry, and key analytical content on the industry dynamics. The report also reviews the competitive landscape and technology offerings. Scope of the Research - Key geographies covered include the US, Ca...

The report provides industry landscape, competitive landscape and industry trends data on the interventional neurology industry . The report provides comprehensive data on the major industry developments affecting the industry, and key analytical content on the industry dynamics. The report also reviews the competitive landscape and technology offerings.


Scope of the Research

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Key sectors covered include Embolic Systems, Navigational Systems, Neurovascular Stents and Aneurysm Clips.
- Annualized industry revenues data from 2003 to 2010, projection forward for 7 years to 2017. Firms shares data for 2010.
- Qualitative analysis of key industry trends, industry drivers, and restraints by each category within interventional neurology industry .
- The report also covers data on the leading industry players, the competitive landscape, and the leading new product development and technologies.
- Key Companies covered include Boston Scientific Corporation, Johnson & Johnson, Covidien plc and Terumo Corporation.

Why Should You Get This Report?

- Develop business strategies by understanding the trends and developments that are driving the interventional neurology industry globally.
- Design and develop your product development, industry ing and sales strategies.
- Develop successful market-entry strategies .
- Identify key players best positioned to take advantage of the emerging industry opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What’s the next big thing in the interventional neurology industry landscape? – Identify, understand and decide.
- Make more informed business decisions from the insightful and in-depth analysis of the global interventional neurology industry and the factors shaping it.

Global General Medicine And Specialty Medicine Industry

1 Table of contents

I Table of contents 3
I. 1 List of Data tables 6
I. 2 List of Charts 8

II Introduction and Overview 9
II. 1 Introduction 9
II. 2 GlobalData Report Guidance 9

III Interventional Neurology: Overview 10
III. 1 Interventional Neurology: March ket Segmentation 10
III. 1.1 Embolic systems 11
III. 1.2 Navigational Systems 11
III. 1.3 Neurovascular Stents 12
III. 1.4 Aneurysm Clips 12

IV Aneurysms: Overview 13
IV. 1 Cerebral Aneurysm 13
IV. 1.1 Types of Cerebral Aneurysm 13
IV. 1.2 Causes 14
IV. 1.3 Pathophysiology 14
IV. 1.4 Epidemiology 15
IV. 1.5 Diagnosis 15

V Interventional Neurology: World March ket Characterization 16
V. 1 Interventional Neurology March ket, Global, Sales (USD Million), Historical data, from 2003 to 2010 16
V. 2 Interventional Neurology March ket, Global, Sales (USD Million), Forecasted data, from 2010 to 2017 17
V. 3 Interventional Neurology March ket, Key Trends 18
V. 3.1 Use of Interventional Neurology Products for Treating Other Diseases is a Emerging Trend in the March ket 18
V. 3.2 Neuroform Stents 19
V. 3.3 Liquid Embolic Systems 19
V. 3.4 Acquisitions of Major Interventional Neurology Firms 20
V. 4 Interventional Neurology, March ket Dynamics 21
V. 4.1 March ket Drivers 21
V. 4.2 Interventional Neurology, March ket Restraints 23

VI Interventional Neurology March ket, Analysis by Sector 25
VI. 1 Embolic Systems, March ket Characterization 25
VI. 1.1 Embolic Systems March ket, Global, Sales (USD Million), Historical data, from 2003 to 2010 25
VI. 1.2 Embolic Systems March ket, Global, Sales (USD Million), Forecasted data, from 2010 to 2017 26
VI. 2 Embolic Systems: March ket Dynamics 27
VI. 2.1 March ket Drivers 27
VI. 2.2 March ket Restraint 27
VI. 3 Navigational Systems: March ket Characterization 28
VI. 3.1 Navigational Systems March ket, Global, Sales (USD Million), Historical data, from 2003 to 2010 28
VI. 3.2 Navigational Systems March ket, Global, Sales (USD Million), Forecasted data, from 2010 to 2017 29
VI. 4 Navigational Systems: March ket Dynamics 30
VI. 4.1 March ket Drivers 30
VI. 4.2 March ket Restraint: 30
VI. 5 Neurovascular Stents: March ket Characterization 31
VI. 5.1 Neurovascular Stents March ket, Global, Sales (USD Million), Historical data, from 2003 to 2010 31
VI. 5.2 Neurovascular Stents March ket, Global, Sales (USD Million), Forecasted data, from 2010 to 2017 32
VI. 6 Neurovascular Stents: March ket Dynamics 33
VI. 6.1 March ket Driver: Technological Advancements is to Drive the March ket 33
VI. 6.2 March ket Restraint: High Risk associated with Stent to Restrain the March ket 33
VI. 7 Aneurysm Clips: March ket Characterization 34
VI. 7.1 Aneurysm Clips March ket, Global, Sales (USD Million), Historical data, from 2003 to 2010 34
VI. 7.2 Aneurysm Clips March ket, Global, Sales (USD Million), Forecasted data, from 2010 to 2017 35
VI. 8 Aneurysm Clips: March ket Dynamics 36
VI. 8.1 March ket Driver: Cost of Treatment Is Driving the March ket 36
VI. 8.2 March ket Restraint: Advancements in the Treatment of Aneurysms is a Restraint to the Clipping March ket 36

VII Interventional Neurology March ket, by Country, Sales (USD Million), from 2003 to 2017 37
VII. 1 Interventional Neurology March ket, The US, Sales (USD Million), Historical data, from 2003 to 2010 37
VII. 2 Interventional Neurology March ket, The US, Sales (USD Million), Forecasted data, from 2010 to 2017 38
VII. 3 Interventional Neurology March ket, Canada, Sales (USD Million), Historical data, from 2003 to 2010 39
VII. 4 Interventional Neurology March ket, Canada, Sales (USD Million), Forecasted data, from 2003 to 2010 40
VII. 5 Interventional Neurology March ket, The UK, Sales (USD Million), Historical data, from 2003 to 2010 41
VII. 6 Interventional Neurology March ket, The UK, Sales (USD Million), Forecasted data, from 2010 to 2017 42
VII. 7 Interventional Neurology March ket, Germany, Sales (USD Million), Historical data, from 2003 to 2010 43
VII. 8 Interventional Neurology March ket, Germany, Sales (USD Million), Forecasted data, from 2010 to 2017 44
VII. 9 Interventional Neurology March ket, France, Sales (USD Million), Historical data, from 2003 to 2010 45
VII. 10 Interventional Neurology March ket, France, Sales (USD Million), Forecasted data, from 2010 to 2017 46
VII. 11 Interventional Neurology March ket, Italy, Sales (USD Million), Historical data, from 2003 to 2010 47
VII. 12 Interventional Neurology March ket, Italy, Sales (USD Million), Forecasted data, from 2010 to 2017 48
VII. 13 Interventional Neurology March ket, Spain, Sales (USD Million), Historical data, from 2003 to 2010 49
VII. 14 Interventional Neurology March ket, Spain, Sales (USD Million), Forecasted data, from 2010 to 2017 50
VII. 15 Interventional Neurology March ket, Japan, Sales (USD Million), Historical data, from 2003 to 2010 51
VII. 16 Interventional Neurology March ket, Japan, Sales (USD Million), Forecasted data, from 2010 to 2017 52
VII. 17 Interventional Neurology March ket, China, Sales (USD Million), Historical data, from 2003 to 2010 53
VII. 18 Interventional Neurology March ket, China, Sales (USD Million), Forecasted data, from 2010 to 2017 54
VII. 19 Interventional Neurology March ket, India, Sales (USD Million), Historical data, from 2003 to 2010 55
VII. 20 Interventional Neurology March ket, India, Sales (USD Million), Forecasted data, from 2010 to 2017 56
VII. 21 Interventional Neurology March ket, Australia, Sales (USD Million), Historical data, from 2003 to 2010 57
VII. 22 Interventional Neurology March ket, Australia, Sales (USD Million), Forecasted data, from 2010 to 2017 58
VII. 23 Interventional Neurology March ket, Brazil, Sales (USD Million), Historical data, from 2003 to 2010 59
VII. 24 Interventional Neurology March ket, Brazil, Sales (USD Million), Forecasted data, from 2010 to 2017 60

VIII Interventional Neurology March ket: Strategic Competitive Assessment 61
VIII. 1 Interventional Neurology: Key March ket Participants 62
VIII. 1.1 Boston Scientific Corporation 62
VIII. 1.2 Johnson & Johnson 65
VIII. 1.3 Covidien plc 68
VIII. 1.4 Terumo Corporation 71

IX Interventional Neurology: Key March keted Products 74
IX. 1 Neuroform3 Microdelivery Stent System 74
IX. 1.1 Product Description 74
IX. 1.2 Features and Benefits 74
IX. 2 Axium Detachable Coil System 74
IX. 2.1 Product Description 74
IX. 2.2 Features and Benefits 74
IX. 3 Onyx HD-500 75
IX. 3.1 Product Description 75
IX. 3.2 Features and Benefits 75
IX. 4 AZUR Peripheral HydroCoil Embolization System 75
IX. 4.1 Product Description 75
IX. 4.2 Features and Benefits 75
IX. 5 DELTAPAQ Microcoils 76
IX. 5.1 Product Description 76
IX. 5.2 Features and Benefits 76

X Interventional Neurology March ket: Strategic Pipeline Assessment 77
X. 1 Interventional Neurology Products under Clinical Development 78
X. 1.1 GORE Embolic Filter 78
X. 1.2 Restore Microcatheter 79
X. 1.3 PHAROS Vitesse Stent 80
X. 1.4 Neucrylate AN 83
X. 1.5 Solitaire FR Revascularization Device 84
X. 1.6 Solitaire AB Neurovascular Remodeling Device 88
X. 1.7 Transcranial Doppler Ultrasound Device 88
X. 2 Interventional Neurology Products under Early Development 88
X. 2.1 AIC Catheter 89
X. 2.2 Balloon Expandable Stent - Next Generation 89
X. 2.3 Catheter Based System 89
X. 2.4 Covered Stent 89
X. 2.5 Flow Diverter 89
X. 2.6 Liquid Embolic System 89
X. 2.7 Neuravi Device 89
X. 2.8 Occlusion Balloons 89
X. 2.9 Self-Expanding Stent 90
X. 2.10 TBI Intervention System 90
X. 3 Interventional Neurology Products under Pre-Clinical Development 90
X. 3.1 Aneurysm Occlusion Device 90
X. 3.2 Brain Cooling Device 90
X. 3.3 Cerebral Aneurysm Repair Device 90
X. 3.4 GP Mechanical Thrombectomy Device 90
X. 3.5 NAVIMAX Spiral Balloon Catheter 90
X. 3.6 Ultrasound Clot Buster 91
X. 4 Interventional Neurology Products in Approval Phase 91
X. 4.1 MicruSphere Microcoil 91
X. 4.2 Cerecyte Microcoil 93
X. 4.3 NeuroFlo Catheter 98
X. 4.4 X Calibur Aneurysm Occlusion Device 110
X. 4.5 Neucrylate AN 111
X. 4.6 Courier Microcatheter 112
X. 4.7 HeliPaq 112
X. 4.8 HeliPaq SR 112
X. 4.9 InterPaq Microcoil 112
X. 4.10 UltiPaq Microcoil 112

XI Interventional Neurology March ket: Strategic Deals Analysis 113
XI. 1 Key Acqusitions 114
XI. 1.1 Stryker Takes Over Boston Scientifics’ Neurovascular Division 114
XI. 1.2 Johnson & Johnson Takes Over Micrus Endovascular 114
XI. 1.3 Covidien Completed Acquisition of ev3 for US$ 2.6 Bln 115

XII Appendix 116
XII. 1 Definitions 117
XII. 1.1 Interventional Neurology 117
XII. 1.2 Embolic Systems 117
XII. 1.3 Navigational Systems 117
XII. 1.4 Neurovascular Stents 117
XII. 1.5 Aneurysm Clips 117
XII. 2 Acronyms 118
XII. 3 Sources 118
XII. 4 Research Methodology 119
XII. 5 Secondary Research 119
XII. 6 Primary Research 119
XII. 7 Models 120
XII. 8 Forecasted data s 120
XII. 9 GlobalData Consulting 120
XII. 10 Contact Us 121
XII. 11 Disclaimer 121

1.1 List of Data tables

Data table 1: Interventional Neurology March ket, Global, Sales (USD Million), from 2003 to 2010 16
Data table 2: Interventional Neurology March ket, Global, Sales (USD Million), from 2010 to 2017 17
Data table 3: Major Acquisitions in Interventional Neurology March ket 20
Data table 4: Embolic Systems March ket, Global, Sales (USD Million), from 2003 to 2010 25
Data table 5: Embolic Systems March ket, Global, Sales (USD Million), from 2010 to 2017 26
Data table 6: Navigational Systems March ket, Global, Sales (USD Million), from 2003 to 2010 28
Data table 7: Navigational Systems March ket, Global, Sales (USD Million), from 2010 to 2017 29
Data table 8: Neurovascular Stents March ket, Sales (USD Million), from 2003 to 2010 31
Data table 9: Neurovascular Stents March ket, Sales (USD Million), from 2010 to 2017 32
Data table 10: Aneurysm Clips March ket, Global, Sales (USD Million), from 2003 to 2010 34
Data table 11: Aneurysm Clips March ket, Global, Sales (USD Million), from 2010 to 2017 35
Data table 12: Interventional Neurology March ket, The US, Sales (USD Million), from 2003 to 2010 37
Data table 13: Interventional Neurology March ket, The US, Sales (USD Million), from 2010 to 2017 38
Data table 14: Interventional Neurology March ket, Canada, Sales (USD Million), from 2003 to 2010 39
Data table 15: Interventional Neurology March ket, Canada, Sales (USD Million), from 2010 to 2017 40
Data table 16: Interventional Neurology March ket, the UK, Sales (USD Million), from 2003 to 2010 41
Data table 17: Interventional Neurology March ket, The UK, Sales (USD Million), from 2010 to 2017 42
Data table 18: Interventional Neurology March ket, Germany, Sales (USD Million), from 2003 to 2010 43
Data table 19: Interventional Neurology March ket, Germany, Sales (USD Million), from 2010 to 2017 44
Data table 20: Interventional Neurology March ket, France, Sales (USD Million), from 2003 to 2010 45
Data table 21: Interventional Neurology March ket, France, Sales (USD Million), from 2010 to 2017 46
Data table 22: Interventional Neurology March ket, Italy, Sales (USD Million), from 2003 to 2010 47
Data table 23: Interventional Neurology March ket, Italy, Sales (USD Million), from 2010 to 2017 48
Data table 24: Interventional Neurology March ket, Spain, Sales (USD Million), from 2003 to 2010 49
Data table 25: Interventional Neurology March ket, Spain, Sales (USD Million), from 2010 to 2017 50
Data table 26: Interventional Neurology March ket, Japan, Sales (USD Million), from 2003 to 2010 51
Data table 27: Interventional Neurology March ket, Japan, Sales (USD Million), from 2010 to 2017 52
Data table 28: Interventional Neurology March ket, China, Sales (USD Million), from 2003 to 2010 53
Data table 29: Interventional Neurology March ket, China, Sales (USD Million), from 2010 to 2017 54
Data table 30: Interventional Neurology March ket, India, Sales (USD Million), from 2003 to 2010 55
Data table 31: Interventional Neurology March ket, India, Sales (USD Million), from 2010 to 2017 56
Data table 32: Interventional Neurology March ket, Australia, Sales (USD Million), from 2003 to 2010 57
Data table 33: Interventional Neurology March ket, Australia, Sales (USD Million), from 2010 to 2017 58
Data table 34: Interventional Neurology March ket, Brazil, Sales (USD Million), from 2003 to 2010 59
Data table 35: Interventional Neurology March ket, Brazil, Sales (USD Million), from 2010 to 2017 60
Data table 36: Interventional Neurology March ket, Market Shares (%), 2010 61
Data table 37: Boston Scientific Corporation, March keted Products 62
Data table 38: Johnson and Johnson, March keted Products 65
Data table 39: Johnson & Johnson, Pipeline Products 66
Data table 40: Covidien, Inc, March keted Products 68
Data table 41: Covidien, Inc, Pipeline Products 68
Data table 42: Terumo Corporation, March keted Products 71
Data table 43: Neuroform Microdelivery Stent System, Features and Benefits 74
Data table 44: Axium Detachable Coil System, Features and Benefits 74
Data table 45: Onyx HD-500, Features and Benefits 75
Data table 46: AZUR Peripheral HydroCoil Embolization System, Features and Benefits 75
Data table 47: DELTAPAQ Microcoils, Features and Benefits 76
Data table 48: Interventional Neurology, Products Under Clinical Development, 2011 78
Data table 49: GORE Embolic Filter, Product Status, 2011 78
Data table 50: GORE Embolic Filter, Clinical Trials, 2011 79
Data table 51: Restore Microcatheter, Product Status, 2011 79
Data table 52: Restore Microcatheter, Clinical Trial, 2011 80
Data table 53: PHAROS Vitesse Stent, Product Status, 2011 80
Data table 54: PHAROS Vitesse Stent, Clinical Trial, 2011 81
Data table 55: Neucrylate AN, Product Status, 2011 83
Data table 56: Neucrylate AN, Clinical Trial, 2011 83
Data table 57: Solitaire FR Revascularization Device, Product Status, 2011 84
Data table 58: Solitaire FR Revascularization Device, Clinical Trial (0), 2011 85
Data table 59: Solitaire FR Revascularization Device, Clinical Trial (1), 2011 86
Data table 60: Interventional Neurology, Products Under Early Development, 2011 88
Data table 61: Interventional Neurology, Products Under Pre-Clinical Development, 2011 90
Data table 62: Interventional Neurology, Products in Approval Phase, 2011 91
Data table 63: MicruSphere Microcoil, Product Status, 2011 91
Data table 64: MicruSphere Microcoil, Clinical Trials, 2011 92
Data table 65: Cerecyte Microcoil, Clinical Trial(0), 2011 93
Data table 66: Cerecyte Microcoil, Clinical Trial(1), 2011 94
Data table 67: Cerecyte Microcoil, Clinical Trial(2), 2011 95
Data table 68: Cerecyte Microcoil, Clinical Trial(3), 2011 96
Data table 69: Cerecyte Microcoil, Clinical Trial(4), 2011 97
Data table 70: NeuroFlo Catheter, Product Status, 2011 98
Data table 71: NeuroFlo Catheter, Clinical Trial (0), 2011 99
Data table 72: NeuroFlo Catheter, Clinical Trial (1), 2011 100
Data table 73: NeuroFlo Catheter, Clinical Trial (2), 2011 101
Data table 74: NeuroFlo Catheter, Clinical Trial (3), 2011 103
Data table 75: NeuroFlo Catheter, Clinical Trial (4), 2011 104
Data table 76: NeuroFlo Catheter, Clinical Trial (5), 2011 106
Data table 77: NeuroFlo Catheter, Clinical Trial (6), 2011 107
Data table 78: NeuroFlo Catheter, Clinical Trial (7), 2011 108
Data table 79: NeuroFlo Catheter, Clinical Trial (8), 2011 109
Data table 80: X Calibur Aneurysm Occlusion Device, Product Status, 2011 110
Data table 81: X Calibur Aneurysm Occlusion Device, Clinical Trials, 2011 111
Data table 82: Neucrylate AN, Product Status, 2011 111
Data table 83: Interventional Neurology March ket, Deal Value (USD Million) and Volume, 2004 – 2010 113

1.2 List of Charts

Chart 1: Interventional Neurology, March ket Segmentation 10
Chart 2: Embolization Coils Procedure 11
Chart 3: Aneurysm Clipping Procedure 12
Chart 4: Types of Cerebral Aneurysms 13
Chart 5: Cerebral Aneurysm, Pathophysiology 14
Chart 6: Cerebral Aneurysm, Disease Burden, 2008 15
Chart 7: Interventional Neurology March ket, Global, Sales (USD Million), from 2003 to 2010 16
Chart 8: Interventional Neurology March ket, Global, Sales (USD Million), from 2010 to 2017 17
Chart 9: Interventional Neurology Treatment, by Disease 18
Chart 10: Interventional Neurology, March ket Dynamics 21
Chart 11: Embolic Systems March ket, Global, Sales (USD Million), from 2003 to 2010 25
Chart 12: Embolic Systems March ket, Global, Sales (USD Million), from 2010 to 2017 26
Chart 13: Navigational Systems March ket, Global, Sales (USD Million), from 2003 to 2010 28
Chart 14: Navigational Systems March ket, Global, Sales (USD Million), from 2010 to 2017 29
Chart 15: Neurovascular Stents March ket, Sales (USD Million), from 2003 to 2010 31
Chart 16: Neurovascular Stents March ket, Sales (USD Million), from 2010 to 2017 32
Chart 17: Aneurysm Clips March ket, Global, Sales (USD Million), from 2003 to 2010 34
Chart 18: Aneurysm Clips March ket, Global, Sales (USD Million), from 2010 to 2017 35
Chart 19: Interventional Neurology March ket, The US, Sales (USD Million), from 2003 to 2010 37
Chart 20: Interventional Neurology March ket, The US, Sales (USD Million), from 2010 to 2017 38
Chart 21: Interventional Neurology March ket, Canada, Sales (USD Million), from 2003 to 2010 39
Chart 22: Interventional Neurology March ket, Canada, Sales (USD Million), from 2010 to 2017 40
Chart 23: Interventional Neurology March ket, The UK, Sales (USD Million), from 2003 to 2010 41
Chart 24: Interventional Neurology March ket, The UK, Sales (USD Million), from 2010 to 2017 42
Chart 25: Interventional Neurology March ket, Germany, Sales (USD Million), from 2003 to 2010 43
Chart 26: Interventional Neurology March ket, Germany, Sales (USD Million), from 2010 to 2017 44
Chart 27: Interventional Neurology March ket, France, Sales (USD Million), from 2003 to 2010 45
Chart 28: Interventional Neurology March ket, France, Sales (USD Million), from 2010 to 2017 46
Chart 29: Interventional Neurology March ket, Italy, Sales (USD Million), from 2003 to 2010 47
Chart 30: Interventional Neurology March ket, Italy, Sales (USD Million), from 2010 to 2017 48
Chart 31: Interventional Neurology March ket, Spain, Sales (USD Million), from 2003 to 2010 49
Chart 32: Interventional Neurology March ket, Spain, Sales (USD Million), from 2010 to 2017 50
Chart 33: Interventional Neurology March ket, Japan, Sales (USD Million), from 2003 to 2010 51
Chart 34: Interventional Neurology March ket, Japan, Sales (USD Million), from 2010 to 2017 52
Chart 35: Interventional Neurology March ket, China, Sales (USD Million), from 2003 to 2010 53
Chart 36: Interventional Neurology March ket, China, Sales (USD Million), from 2010 to 2017 54
Chart 37: Interventional Neurology March ket, India, Sales (USD Million), from 2003 to 2010 55
Chart 38: Interventional Neurology March ket, India, Sales (USD Million), from 2010 to 2017 56
Chart 39: Interventional Neurology March ket, Australia, Sales (USD Million), from 2003 to 2010 57
Chart 40: Interventional Neurology March ket, Australia, Sales (USD Million), from 2010 to 2017 58
Chart 41: Interventional Neurology March ket, Brazil, Sales (USD Million), from 2003 to 2010 59
Chart 42: Interventional Neurology March ket, Brazil, Sales (USD Million), from 2010 to 2017 60
Chart 43: Interventional Neurology March ket, Market Shares (%), 2010 61
Chart 44: Boston Scientific, SWOT 63
Chart 45: Johnson & Johnson, SWOT 66
Chart 46: Covidien, Inc, SWOT 69
Chart 47: Terumo Corporation, SWOT 72
Chart 48: Interventional Neurology March ket, World Pipeline Products 77
Chart 49: Interventional Neurology March ket, Deal Value (USD Million) and Volume, 2004 – 2010 113

Companies Mentioned
Boston Scientific Corporation
Johnson & Johnson
Covidien plc
Terumo Corporation